Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Boehringer Ingelheim
McKinsey
Johnson and Johnson
Merck

Last Updated: August 13, 2022

CLINICAL TRIALS PROFILE FOR FARYDAK


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Farydak

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00859222 ↗ LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed Beth Israel Deaconess Medical Center Phase 1/Phase 2 2009-03-01 The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
NCT00859222 ↗ LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed Brigham and Women's Hospital Phase 1/Phase 2 2009-03-01 The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
NCT00859222 ↗ LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed Genentech, Inc. Phase 1/Phase 2 2009-03-01 The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
NCT00859222 ↗ LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed Massachusetts General Hospital Phase 1/Phase 2 2009-03-01 The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Farydak

Condition Name

Condition Name for Farydak
Intervention Trials
Recurrent Plasma Cell Myeloma 4
Refractory Plasma Cell Myeloma 4
Multiple Myeloma 2
Diffuse Intrinsic Pontine Glioma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Farydak
Intervention Trials
Neoplasms, Plasma Cell 5
Multiple Myeloma 5
Glioma 3
Graft vs Host Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Farydak

Trials by Country

Trials by Country for Farydak
Location Trials
United States 24
Italy 11
Australia 5
Germany 4
Korea, Republic of 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Farydak
Location Trials
Texas 4
Massachusetts 3
Ohio 2
California 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Farydak

Clinical Trial Phase

Clinical Trial Phase for Farydak
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Farydak
Clinical Trial Phase Trials
Recruiting 5
Active, not recruiting 2
Terminated 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Farydak

Sponsor Name

Sponsor Name for Farydak
Sponsor Trials
Novartis 4
National Cancer Institute (NCI) 4
Novartis Pharmaceuticals 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Farydak
Sponsor Trials
Other 18
Industry 13
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Harvard Business School
Express Scripts
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.